Novadip Biosciences, a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has raised an additional EUR 40 million ($39.1 million) in a Series B equity round and non-dilutive funding.